Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | Updated analysis from MOUNTAINEER: tucatinib and trastuzumab for HER2-positive mCRC

John Strickler, MD, Duke Cancer Center, Durham, NC, presents additional analyses of MOUNTAINEER (NCT03043313), a Phase II study of tucatinib and trastuzumab for HER2-positive metastatic colorectal cancer (mCRC). Tucatinib monotherapy and tucatinib with trastuzumab after crossover were well tolerated, consistent with the primary analysis, with 18% of patients who crossed over achieving a response. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.